BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA

Reuters01-08

BRIEF-Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Read Out Of Type B Meeting With The FDA

Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O:

PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASES
PLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LM
PLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFIT
PLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIAL

Source text: ID:nGNX86QCSM

Further company coverage: PSTV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601361254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 20:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601361254","market":"fut","top_or_hot":-1,"title":"BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Read Out Of Type B Meeting With The FDA </title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Plus Therapeutics Inc <span>PSTV.O</span>:</p><ul><li><p>PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASES</p></li><li><p>PLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LM</p></li><li><p>PLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFIT</p></li><li><p>PLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIAL</p></li></ul><p>Source text: <span>ID:nGNX86QCSM</span></p><p>Further company coverage: <span>PSTV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 20:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Plus <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Read Out Of Type B Meeting With The FDA </title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span>Plus Therapeutics Inc <span>PSTV.O</span>:</p><ul><li><p>PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASES</p></li><li><p>PLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LM</p></li><li><p>PLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFIT</p></li><li><p>PLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIAL</p></li></ul><p>Source text: <span>ID:nGNX86QCSM</span></p><p>Further company coverage: <span>PSTV.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSTV","symbol_name":"Plus Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA7R6D9B:1","article_id":"2601361254","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601361254","pubTimestamp":1767877031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O:PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSTV":"Plus Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BRIEF-Plus Therapeutics宣布宣读与FDA的B型会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSTV":0.9},"content_text":"BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA Jan 8 (Reuters) - Plus Therapeutics Inc PSTV.O:PLUS THERAPEUTICS ANNOUNCES READ OUT OF TYPE B MEETING WITH THE FDA WITH GOAL OF ACCELERATING APPROVAL OF REYOBIQ™ FOR LEPTOMENINGEAL METASTASESPLUS THERAPEUTICS INC - FDA INDICATES ACCELERATED APPROVAL MAY BE APPROPRIATE FOR LMPLUS THERAPEUTICS INC - FDA RECOMMENDS STUDY EVALUATE ENDPOINT WITH CLINICAL BENEFITPLUS THERAPEUTICS INC - FDA CONVEYS MULTIPLE HISTOLOGIES MAY BE INCORPORATED IN TRIALSource text: ID:nGNX86QCSMFurther company coverage: PSTV.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601361254","isCrawlerRequest":true}